Risk of Violating the Fair Competition Code for the Medical Device Industry
First written in FY2021. 10 of 11 entries say "Restated". Latest entry: FY2025.
2 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The fair competition code was established under the Act against Unjustifiable Premiums and Misleading Representations and jointly authorized by the Commissioner of the Consumer Affairs Agency and the Japan Fair Trade Commission. Violations may result in penalties, including fines. This could affect the Company's performance and other matters through reputational damage and other consequences.」
The risks of fines, reputational damage and an impact on performance resulting from violations of the fair competition code in the medical equipment industry continue. - FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new occurrences of major risks that management recognizes could materially affect the financial position, operating results or cash flows of the consolidated companies among the matters concerning business conditions and financial matters described in this interim report, nor any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risks of fines, reputational damage and an impact on performance resulting from violations of the fair competition code in the medical equipment industry. - FY2024RestatedAnnual report
「The fair competition code was established under the Act against Unjustifiable Premiums and Misleading Representations and jointly authorized by the Commissioner of the Consumer Affairs Agency and the Japan Fair Trade Commission. Violations may result in penalties, including fines. This could affect the Company's performance and other matters through reputational damage and other consequences.」
The risks of fines, reputational damage and an impact on performance resulting from violations of the fair competition code in the medical equipment industry continue. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risks of fines, reputational damage and an impact on performance resulting from violations of the fair competition code in the medical equipment industry. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risks of fines, reputational damage and an impact on performance resulting from violations of the fair competition code in the medical equipment industry. - FY2023RestatedAnnual report
「The fair competition code was established under the Act against Unjustifiable Premiums and Misleading Representations and jointly authorized by the Commissioner of the Consumer Affairs Agency and the Japan Fair Trade Commission. Violations may result in penalties, including fines. This could affect the Company's performance and other matters through reputational damage and other consequences.」
The risks of fines, reputational damage and an impact on performance resulting from violations of the fair competition code in the medical equipment industry remain. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risk of violating the fair competition code in the medical equipment industry. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risk of violating the fair competition code in the medical equipment industry. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risk of violating the fair competition code in the medical equipment industry. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The company concluded that there had been no material change in the risk of violating the fair competition code in the medical equipment industry. - FY2021First statedAnnual report
「The fair competition code was established under the Act against Unjustifiable Premiums and Misleading Representations and jointly authorized by the Commissioner of the Consumer Affairs Agency and the Japan Fair Trade Commission. Violations may result in penalties, including fines. This could affect the Company's performance and other matters through reputational damage and other consequences.」
The company has identified as a new risk the possibility that violations of the fair competition code in the medical equipment industry could affect performance and other matters through fines and reputational damage.